Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 5
2008 2
2011 1
2012 3
2013 1
2016 1
2019 1
2020 8
2021 18
2022 7
2023 7
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Kristensen LE, et al. Among authors: modesto i. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17. Ann Rheum Dis. 2023. PMID: 36931693 Free PMC article. Clinical Trial.
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Sandborn WJ, et al. Among authors: modesto i. Aliment Pharmacol Ther. 2022 Feb;55(4):464-478. doi: 10.1111/apt.16712. Epub 2021 Dec 1. Aliment Pharmacol Ther. 2022. PMID: 34854095 Free PMC article.
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Modesto I, Guo X, Mundayat R, Su C, Vranic I, Panés J. Sandborn WJ, et al. Among authors: modesto i. J Crohns Colitis. 2023 Apr 3;17(3):338-351. doi: 10.1093/ecco-jcc/jjac141. J Crohns Colitis. 2023. PMID: 36124702 Free PMC article. Clinical Trial.
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Peyrin-Biroulet L, Dubinsky MC, Sands BE, Panés J, Schreiber S, Reinisch W, Feagan BG, Danese S, Yarur AJ, D'Haens GR, Goetsch M, Wosik K, Keating M, Lazin K, Wu J, Modesto I, McDonnell A, Bartolome L, Vermeire S. Peyrin-Biroulet L, et al. Among authors: modesto i. J Crohns Colitis. 2024 Aug 14;18(8):1270-1282. doi: 10.1093/ecco-jcc/jjae038. J Crohns Colitis. 2024. PMID: 38613425 Free PMC article. Clinical Trial.
Infliximab and ulcerative colitis.
Cottone M, Mocciaro F, Modesto I. Cottone M, et al. Among authors: modesto i. Expert Opin Biol Ther. 2006 Apr;6(4):401-8. doi: 10.1517/14712598.6.4.401. Expert Opin Biol Ther. 2006. PMID: 16548766 Review.
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme.
Regueiro M, Siegmund B, Yarur AJ, Steinwurz F, Gecse KB, Goetsch M, Bhattacharjee A, Wu J, Green J, McDonnell A, Crosby C, Lazin K, Branquinho D, Modesto I, Abreu MT. Regueiro M, et al. Among authors: modesto i. J Crohns Colitis. 2024 Oct 15;18(10):1596-1605. doi: 10.1093/ecco-jcc/jjae060. J Crohns Colitis. 2024. PMID: 38700040 Free PMC article. Clinical Trial.
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod.
Magro F, Peyrin-Biroulet L, Sands BE, Danese S, Jairath V, Goetsch M, Bhattacharjee A, Wu J, Branquinho D, Modesto I, Feagan BG. Magro F, et al. Among authors: modesto i. Clin Gastroenterol Hepatol. 2024 Jul 31:S1542-3565(24)00681-5. doi: 10.1016/j.cgh.2024.07.010. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39089519 Free article.
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
Vermeire S, Sands BE, Peyrin-Biroulet L, D'Haens GR, Panés J, Yarur AJ, Wolf DC, Ritter T, Schreiber S, Woolcott JC, Modesto I, Keating M, Shan K, Wu J, Chiorean MV, Baert F, Dubinsky MC, Goetsch M, Danese S, Feagan BG. Vermeire S, et al. Among authors: modesto i. J Crohns Colitis. 2024 Nov 4;18(11):1780-1794. doi: 10.1093/ecco-jcc/jjae079. J Crohns Colitis. 2024. PMID: 38877972 Free PMC article. Clinical Trial.
Mesalazine for the treatment of inflammatory bowel disease.
Criscuoli V, Modesto I, Orlando A, Cottone M. Criscuoli V, et al. Among authors: modesto i. Expert Opin Pharmacother. 2013 Aug;14(12):1669-78. doi: 10.1517/14656566.2013.808622. Epub 2013 Jun 17. Expert Opin Pharmacother. 2013. PMID: 23767798 Review.
59 results